Loading...
•
Dec 31, 2021
Zevra Q4 2021 Earnings Report
KemPharm reported financial results for the fourth quarter and year ended December 31, 2021.
Key Takeaways
KemPharm reported Q4 2021 revenue of $2.6 million and a net loss of ($2.7) million. The company's cash, cash equivalents, and long-term investments totaled $127.8 million as of December 31, 2021.
KemPharm advanced on multiple fronts during the fourth quarter of 2021 and into early 2022, focusing on rare CNS and neurodegenerative conditions.
Strategic focus on developing and commercializing therapeutics targeting rare CNS and neurodegenerative conditions starting with KP1077.
Data from Phase 1 clinical trial validates selection of KP1077 as lead product candidate.
Company expects to file IND application for KP1077 as early as the second quarter of 2022 and initiate a Phase 2 clinical trial later in the year.
Forward Guidance
KemPharm's existing cash, cash equivalents and long-term investments are expected to be sufficient to continue operations through and beyond 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...